Updates

** Drug developer Arvinas' ARVN.O shares fall 50.3% to $8.73, hitting all-time low

** Pfizer PFE.N and ARVN say their experimental breast cancer treatment failed to delay progression of the disease in a broader group of patients in a late-stage trial

** Pfizer's PFE.N shares fall 1.6% to $26.22

** Arvinas says vepdegestrant failed to show statistically significant improvements in the intent-to-treat $(ITT)$ population

** The ITT population represents a substantially larger group of patients, which could have led to a ~$4 bln in additional revenue upside - Brokerage BMO Capital Markets

** But the drug helped improve progression-free survival in a subgroup of patients with a genetic form of the most common type of breast cancer

** As of last close, ARVN down 62.7% in past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))